Search Results

You are looking at 11 - 20 of 71 items for :

Clear All
Full access

Andrew D. Zelenetz and Pamela S. Becker

granulocyte colony-stimulating factor (G-CSF) filgrastim-sndz. Filgrastim-sndz is now listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors (MGFs) and is part of many drug formularies. The oncology community

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer and Maria Ho

®. Filgrastim and pegfilgrastim, both granulocyte-colony stimulating factors (G-CSFs), currently have FDA approval for use in the prevention of chemotherapy-induced neutropenia. In contrast, the labeled indication for sargramostim, a granulocyte

Full access

Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt and Michael Westmoreland

mental health. 4 Filgrastim and pegfilgrastim, both granulocyte-colony stimulating factors (G-CSFs), are currently FDA approved for use in preventing chemotherapy-induced neutropenia. In contrast, the labeled indication for sargramostim, a granulocyte

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns and Lenora Pluchino

complications may enhance the cost-effectiveness. These NCCN Guidelines focus on the 2 MGFs that have shown the most promise in terms of clinical use: granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM

Full access

Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt and Pamela S. Becker

granulocyte-colony stimulating factors (G-CSFs), granulocyte-macrophage colony-stimulating factors, erythropoiesis-stimulating agents (ESAs), and other measures to manage cancer and chemotherapy-associated cytopenias. 11 , 12 These guidelines are based on the

Full access

Martha Wadleigh and Richard M. Stone

myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group . J Clin Oncol 1996 ; 14 : 2150 – 2159 . 8 Amadori S Suciu S Jehn U . Use of glycosylated recombinant human G-CSF

Full access

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller and Lenora A. Pluchino

., Inc. Overview Myeloid growth factors (MGFs), such as granulocyte colony-stimulating factors (G-CSFs), are hematopoietic growth factors (HGFs) that regulate the growth and differentiation of cells in the myeloid lineage. 1 Pharmacologic G-CSFs, such as

Full access

Jeffrey Crawford and George M. Rodgers

chemotherapy. There are 2 main strategies for prevention: dose reductions and delays in chemotherapy, and the use of MGFs, which include granulocyte colony-stimulating factors (G-CSF; ie, filgrastim and tbo-filgrastim), granulocyte-macrophage colony

Full access

Bradford R. Hirsch and Gary H. Lyman

introduction in the United States. The European Union (EU) provided a pathway for approval in 2004 1 and has since provided guidance on, and seen the approval of, various biosimilars, including erythropoietins, 2 , 3 granulocyte colony-stimulating factors (G-CSF

Full access

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente and Francisco Ayala de la Peña

previous neuropathy, tumor data, chemotherapy regimen, initial dose level of paclitaxel, total dose of paclitaxel, granulocyte colony-stimulating factor (G-CSF) administration, date of first documented PIPN, maximum grade of PIPN, delayed or reduced doses